INFLIXIMAB THERAPY AND THE CENTRAL NERVOUS DEMYELINATION IN PATIENTS WITH KAWASAKI DISEASE

We performed brain magnetic resonance imagingin 14 patients with Kawasaki diseasewho were treated with infliximab(IFX) at 56 months of age (32–62 months of age) and 23 months (5–35 months) after IFX therapy. Magnetic resonance imagingshowed no finding of the central nervous demyelination. IFX th